论文部分内容阅读
目的了解维思通治疗儿童期首发精神分裂症患者的疗效和安全性。方法对70例年龄<14岁首发精神分裂症患儿用维思通治疗6周,以阳性和阴性症状量表(PANSS)和简明精神病评定量表(BPRS)评定临床疗效。以副反应量表(TESS)和实验室监测评价安全性,于基线时,实验第1、2、4、6周末分别评定各量表。统计方法为描述性分析和配对t检验。结果共收集有效病例70例,其中基本痊愈34.3%(24/70),显著进步45.7%(32/70),好转10%(7/70)和无效10%(7/70)。BPRS总分、PANSS总分、PANSS各分量表分值治疗前后比较差异均有显著性(P<0.01),维思通对阳性、阴性症状以及一般精神病性症状均有良好疗效。副反应主要为锥体外系反应。结论对儿童期首发精神分裂症,维思通疗效较好,安全性高。
Objective To investigate the efficacy and safety of VST in the treatment of first-episode schizophrenia in childhood. Methods Seventy children with first-episode schizophrenia <14 years of age were treated with VST for 6 weeks. The positive and negative symptom scales (PANSS) and the Concise Mental Illness Rating Scale (BPRS) were used to assess the clinical efficacy. Safety was assessed by TESS and laboratory monitoring. At baseline, the scales were assessed at the end of the first, second, fourth and sixth week of the experiment. Statistical methods were descriptive analysis and paired t-test. Results A total of 70 effective cases were collected, of which 34.3% (24/70) were basically cured, 45.7% (32/70) significantly improved, 10% (7/70) improved and 10% (7/70) ineffective. BPRS total score, PANSS total score, PANSS scores before and after treatment were significantly different (P <0.01), VST on positive, negative symptoms and general psychiatric symptoms have a good effect. Side effects are mainly extrapyramidal reactions. Conclusions First-episode schizophrenia in childhood, VST is effective and safe.